NeuroPace FY2029 EPS Estimate Boosted by Leerink Partnrs

Key Points

• Leerink Partners raised their FY2029 earnings per share (EPS) estimate for NeuroPace from $0.46 to $0.57, while the consensus estimate for the company’s full-year earnings remains at ($1.00) per share.
• NeuroPace reported a quarterly EPS of (0.26), falling short of the consensus estimate and having a revenue of $23.52 million, which surpassed expectations.
• The stock has a consensus rating of Buy with a target price averaging around $16.60, indicating positive sentiment among multiple analysts.

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Stock analysts at Leerink Partnrs increased their FY2029 earnings per share (EPS) estimates for shares of NeuroPace in a research note issued to investors on Tuesday, August 12th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of $0.57 for the year, up from their previous estimate of $0.46. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $23.52 million during the quarter, compared to analyst estimates of $23.08 million. NeuroPace had a negative net margin of 29.29% and a negative return on equity of 184.84%.

Several other equities research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a report on Wednesday, May 14th. Wells Fargo & Company reduced their target price on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating for the company in a report on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $17.00 price target on shares of NeuroPace in a research note on Wednesday, May 14th. Finally, HC Wainwright began coverage on shares of NeuroPace in a research note on Wednesday, May 28th. They issued a "buy" rating and a $18.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $16.60.

NeuroPace Stock Performance

NPCE traded down $0.51 during midday trading on Thursday, reaching $8.82. The company had a trading volume of 38,442 shares, compared to its average volume of 275,345. The company has a debt-to-equity ratio of 2.46, a quick ratio of 5.70 and a current ratio of 6.63. NeuroPace has a 12-month low of $5.45 and a 12-month high of $18.98. The business has a 50-day moving average price of $10.09 and a two-hundred day moving average price of $11.81. The stock has a market cap of $289.12 million, a PE ratio of -10.50 and a beta of 1.89.

Institutional Trading of NeuroPace

A number of institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in shares of NeuroPace by 440.4% in the 4th quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company's stock valued at $725,000 after purchasing an additional 52,829 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of NeuroPace by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 322,973 shares of the company's stock worth $3,615,000 after purchasing an additional 5,781 shares during the period. Wells Fargo & Company MN grew its stake in shares of NeuroPace by 54.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock worth $73,000 after purchasing an additional 2,279 shares during the period. Barclays PLC grew its stake in shares of NeuroPace by 33.8% during the 4th quarter. Barclays PLC now owns 27,609 shares of the company's stock worth $309,000 after purchasing an additional 6,976 shares during the period. Finally, Walleye Capital LLC acquired a new stake in shares of NeuroPace during the 4th quarter worth approximately $319,000. 78.83% of the stock is currently owned by institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.